JasonJalilMD

Forensic Psychiatry, Geriatric Psychiatry, Neuropsychiatry

Faculty

Dr. Jalil is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
300 UCLA Medical Plz
Ste 2200
Los Angeles, CA 90095
Phone+1 310-825-9989
Is this information wrong?

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Geriatric Psychiatry, 2016 - 2017
UCLA David Geffen School of Medicine/UCLA Medical CenterChief Residency, Psychiatry, 2015 - 2016
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Psychiatry, 2012 - 2016
Tel Aviv University SacklerClass of 2012, MD

PubMed

102 citations
Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade.
Antoni Ribas, Begoña Comin-Anduix, James S. Economou, Timothy R. Donahue, Pilar de la Rocha
Clinical Cancer Research. 2009-01-01
122 citations
CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans
Rong Rong Huang, Jason Jalil, James S. Economou, Bartosz Chmielowski, Richard C. Koya
Clinical Cancer Research. 2011-06-15
119 citations
The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations.
Begoña Comin-Anduix, Thinle Chodon, Hooman Sazegar, Douglas Matsunaga, Stephen Mock
Clinical Cancer Research. 2010-12-15

Journal Articles

Brain health consequences of digital technology use
Gary W. Small; Jooyeon Lee; Aaron Kaufman; Jason Jalil, MD; Prabha Siddarth, PhD; Himaja Gaddipati, DO, ScM; Teena D. Moody, PhD; Susan Y. Bookheimer, PhD., Dialogues Clinical Neuroscience